9 top oncology stocks to buy in 2024

The best oncology stocks depend on your portfolio and investment goals — while volatility can be ideal for day traders, long-term investors will want to look to stocks with steadier gains over time.

9 popular oncology stocks picks to buy in 2024

We round up a selection of stocks in or related to the cancer industry, weighting the list more heavily towards popular mid- and large-cap US stocks.

1. Amgen (AMGN)
2. Bristol-Myers Squibb Company (BMY)
3. Five Prime Therapeutics (FPRX)
4. Gilead Sciences (GILD)
5. Novartis AG ADR (NVS)
6. Cardiff Oncology (CRDF)
7. Surface Oncology (SURF)
8. Trillium Therapeutics (TRIL)
9. Mersana Therapeutics (MRSN)

Compare premium accounts that help you research stocks

The oncology stocks industry is affected by a range of complex factors such as trade policies, regulations, and fluctuating supply and demand. So when considering oncology stocks to buy, it's important that you have access to vital information about a company's financial health, leadership team, and market positioning.

Our picks for platforms with research tools

How to invest in oncology stocks

1. Choose an online stock trading platform. Choose from our Top Picks above, use our comparison table below or jump straight to the best stock trading apps of 2024.
2. Sign up for an account. Provide your personal information and sign up.
3. Set up a funding method to pay for the transaction. Deposit funds into your account by linking your banking information.
4. Choose the stocks you want to buy. Search for the stock by name or ticker symbol like AMGN or BMY.
5. Place your order. Buy the stock. It's that simple.

Take a deeper dive into oncology stocks

If you're interested in investing in the cancer industry, take a closer look at what companies in this industry do and how the stocks have historically performed. Keep in mind that positive past performance doesn't guarantee that a stock will continue to rise in the future.

---

1. Amgen (AMGN)

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

Amgen stock opened the day at $265.72 after a previous close of $269.38. The latest price was $269.98 (25-minute delay). Amgen is listed on the NASDAQ, has a trailing 12-month revenue of around USD28.2 billion and employs 26,700 staff.

• Market capitalization: $146,436,014,080
• P/E ratio: 21.8758
• PEG ratio: 2.3869

Back to top

---

2. Bristol-Myers Squibb Company (BMY)

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

Bristol-Myers Squibb Company stock opened the day at $44.68 after a previous close of $44.70. The latest price was $44.85 (25-minute delay). Bristol-Myers Squibb Company is listed on the NYSE, has a trailing 12-month revenue of around USD$45 billion and employs 34,100 staff.

• Market capitalization: $99,027,492,864
• P/E ratio: 12.658
• PEG ratio: 2.2361

Back to top

---

3. Five Prime Therapeutics (FPRX)

Five Prime Therapeutics, Inc. , a clinical-stage biotechnology company, focuses on the development of immuno-oncology and targeted cancer therapies. The company's product candidates comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b to treat patients with gastric or gastroesophageal junction and GEJ cancer; FPT155, a soluble CD80 fusion protein that enhances co-stimulation of T cells through CD28 that is in Phase Ia/1b clinical trial for patients with solid tumors; and BMS-986258, an anti-T cell immunoglobulin and mucin domain-3 antibody, which is in Phase I/II clinical trial in combination with Opdivo in patients with advanced malignant tumors.

Five Prime Therapeutics is listed on the NASDAQ, has a trailing 12-month revenue of around USD$13.2 million and employs 51 staff.

• Market capitalization: $1,769,735,936
• PEG ratio: 0.14

Back to top

---

4. Gilead Sciences (GILD)

Gilead Sciences, Inc. , a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

Gilead Sciences stock opened the day at $65.50 after a previous close of $65.27. The latest price was $65.42 (25-minute delay). Gilead Sciences is listed on the NASDAQ, has a trailing 12-month revenue of around USD$27.1 billion and employs 18,000 staff.

• Market capitalization: $83,646,750,720
• P/E ratio: 14.9067
• PEG ratio: 0.421

Back to top

---

5. Novartis AG ADR (NVS)

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.

Novartis AG ADR stock opened the day at $97.76 after a previous close of $99.06. The latest price was $97.44 (25-minute delay). Novartis AG ADR is listed on the NYSE, has a trailing 12-month revenue of around USD$47.7 billion and employs 76,057 staff.

• Market capitalization: $198,949,273,600
• P/E ratio: 23.7268
• PEG ratio: 5.0912

Back to top

---

6. Cardiff Oncology (CRDF)

Cardiff Oncology, Inc. , a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.

Cardiff Oncology stock opened the day at $4.06 after a previous close of $3.99. The latest price was $4.07 (25-minute delay). Cardiff Oncology is listed on the NASDAQ, has a trailing 12-month revenue of around USD$488,000 and employs 31 staff.

• Market capitalization: $178,262,032

Back to top

---

7. Surface Oncology (SURF)

Surface Oncology, Inc. , a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 which is in phase II clinical trial targeting interleukin 27; GSK4381562, an antibody targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 that is in phase 1/2 clinical trials targeting the chemokine receptor CCR8.

Surface Oncology is listed on the NASDAQ and employs 35 staff.

• Market capitalization: $65,690,464

Back to top

---

8. Trillium Therapeutics (TRIL)

As of November 17, 2021, Trillium Therapeutics Inc. was acquired by Pfizer Inc. Trillium Therapeutics Inc.

Trillium Therapeutics is listed on the NASDAQ, has a trailing 12-month revenue of around USD$43,000 and employs 33 staff.

• Market capitalization: $1,936,107,904
• PEG ratio: 0

Back to top

---

9. Mersana Therapeutics (MRSN)

Mersana Therapeutics, Inc. , a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC.

Mersana Therapeutics stock opened the day at $2.84 after a previous close of $2.85. The latest price was $2.94 (25-minute delay). Mersana Therapeutics is listed on the NASDAQ, has a trailing 12-month revenue of around USD$36.9 million and employs 123 staff.

• Market capitalization: $346,926,560
• PEG ratio: 0

Back to top

Compare more stock trading platforms to invest in oncology stocks

Compare online trading platforms by fees, asset types and bonuses to find the best for your investment in oncology stocks.

Bottom line

While it’s possible to turn a profit investing in oncology stocks, keep in mind that — like any investment — oncology stocks are not immune to risk. These stocks are subject to fluctuating conditions — both in the market and in the cancer industry, so carefully vet your picks before you invest. And if you’re new to investing, or if it’s been awhile since you’ve taken a critical look at your investing accounts, compare brokers to make sure you’re getting the best features in your trading account.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.